Gene therapy trials
Executive Summary
FDA's Biological Response Modifiers Advisory Committee will discuss long-term follow-up of patients in gene therapy clinical trials Oct. 24 at 9 a.m.. The committee rejected FDA's initial long-term follow-up proposal, a tiered system based on gene transfer vector, at its April 6 meeting (1"The Pink Sheet" April 16, p. 31). The committee will discuss vector design, manufacture and preclinical studies of lentivirus vectors in gene therapy trials Oct. 25, beginning at 8 a.m. On Oct. 26, committee members will discuss development of a lentivirus vector gene transfer product for people with HIV beginning at 8 a.m. The meeting will be held all three days at the Holiday Inn, Gaithersburg, MdYou may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: